In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols Babesia test for samples received on April 20, 2020 at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Be watching for details on an upcoming webinar that will provide you with an overview of implementing this testing.
Check out the Communication page for the complete details by clicking the link: Communications
This is the first update to the original CTS communication distributed on July 6th. As previously co...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...